Skip to main content
QTRX
NASDAQ Industrial Applications And Services

Quanterix Appoints Former Illumina CCO Everett Cunningham as CEO with Significant Performance-Based Equity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$6.64
Mkt Cap
$304.087M
52W Low
$4.05
52W High
$12.21
52W Position info
64% above low
Off High info
46% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

QTRX sits 64% above its 52-week low of $4.05.

Summary

Quanterix Corporation announced the appointment of Everett Cunningham, former Chief Commercial Officer of Illumina, as its new President and CEO, effective January 19, 2026, alongside a positive preliminary financial outlook for FY2025.


Key Events · Executive and Board Changes · QTRX

  • New CEO Appointed

    Everett Cunningham, previously Chief Commercial Officer at Illumina, was appointed President and CEO, effective January 19, 2026. He also joins the Board of Directors.

  • Significant Equity Incentives

    Mr. Cunningham received 1,070,000 time-based restricted stock units (RSUs) and 813,750 performance-based RSUs, with vesting tied to stock price targets of $10, $15, and $20 per share.

  • CEO Departure

    Masoud Toloue, Ph.D., resigned as President and CEO and from the Board, effective January 19, 2026, receiving severance and accelerated equity vesting.

  • Positive Financial Outlook

    The company expects to exceed its revenue and cash guidance for the full fiscal year ended December 31, 2025.


Analysis · QTRX · Industrial Applications And Services

The appointment of Everett Cunningham as CEO is a highly significant development for Quanterix. Mr. Cunningham brings extensive leadership experience from major life sciences and healthcare companies like Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics, and Pfizer, which is a strong positive signal for the company's strategic direction and commercial execution. His compensation package includes substantial performance-based restricted stock units tied to ambitious stock price targets of $10, $15, and $20, strongly aligning his incentives with shareholder value creation. This leadership change, coupled with the company's expectation to exceed its revenue and cash guidance for fiscal year 2025, suggests a renewed focus on growth and operational improvement.

At the time of this filing, QTRX was trading at $6.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $304.1M. The 52-week trading range was $4.05 to $12.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QTRX - Latest Insights

QTRX
Jun 10, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.07
Real-time Price: $3.48 info
Change: +$0.410 (+13%) info
Market Cap: $164.4M info
QTRX
Jun 10, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $3.48 info
Change: +$0.280 (+9%) info
Market Cap: $164.4M info
QTRX
Jun 09, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.67
Real-time Price: $3.48 info
Change: -$0.190 (-5%) info
Market Cap: $164.4M info
QTRX
May 26, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $3.48 info
Change: +$0.800 (+30%) info
Market Cap: $164.4M info
QTRX
May 12, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.91
Real-time Price: $3.48 info
Change: +$0.570 (+20%) info
Market Cap: $164.4M info